JP2009519979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519979A5 JP2009519979A5 JP2008545992A JP2008545992A JP2009519979A5 JP 2009519979 A5 JP2009519979 A5 JP 2009519979A5 JP 2008545992 A JP2008545992 A JP 2008545992A JP 2008545992 A JP2008545992 A JP 2008545992A JP 2009519979 A5 JP2009519979 A5 JP 2009519979A5
- Authority
- JP
- Japan
- Prior art keywords
- exo
- hept
- diamine
- racemic
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 -C 1 -C 6 haloalkyl Chemical group 0.000 claims 77
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 9
- PFXXTYUSZRFQHC-UHFFFAOYSA-N 2-methylhept-5-enamide Chemical compound CC=CCCC(C)C(N)=O PFXXTYUSZRFQHC-UHFFFAOYSA-N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- QFVJQOMTGRIFGV-UHFFFAOYSA-N 2-imino-1-phenyl-7H-purin-6-amine Chemical compound NC1=NC2=NC=NC2=C(N)N1C1=CC=CC=C1 QFVJQOMTGRIFGV-UHFFFAOYSA-N 0.000 claims 3
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 2
- CTZMPBILUBWBEV-UHFFFAOYSA-N NC1=NC(N)=C2C=CN=C2N1C1=CC=CC=C1 Chemical compound NC1=NC(N)=C2C=CN=C2N1C1=CC=CC=C1 CTZMPBILUBWBEV-UHFFFAOYSA-N 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- ZTUUVDYQBLRAAC-UHFFFAOYSA-N bicyclo[2.2.1]hept-2-ene-5-carboxamide Chemical compound C1C2C(C(=O)N)CC1C=C2 ZTUUVDYQBLRAAC-UHFFFAOYSA-N 0.000 claims 2
- 150000004985 diamines Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 claims 2
- HGUZNMOMWFNAIA-LYJAMZSYSA-N (1r,3s,4r,5s)-4-[[2-[4-(4-cyclohexylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]amino]-n,4,6,6-tetramethylbicyclo[3.1.1]heptane-3-carboxamide Chemical compound N([C@@]1([C@@]2([H])C[C@@](C2(C)C)(C[C@@H]1C(=O)NC)[H])C)C(C=1SC=CC=1N=1)=NC=1NC(C=C1)=CC=C1N(CC1)CCN1C1CCCCC1 HGUZNMOMWFNAIA-LYJAMZSYSA-N 0.000 claims 1
- ZKLXTNAQPVKTED-GUYJKWIASA-N (1s,2s,3r,4r)-3-[[2-(1h-indol-5-ylamino)-7h-purin-6-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound C1=C2NC=CC2=CC(NC=2NC(=C3N=CN=C3N=2)N[C@H]2[C@H]([C@@]3([H])C[C@@]2(C=C3)[H])C(N)=O)=C1 ZKLXTNAQPVKTED-GUYJKWIASA-N 0.000 claims 1
- BCCAFVDIHPOCSV-LCLWPZTBSA-N (1s,2s,3r,4r)-3-[[2-[4-(pyridin-4-ylmethyl)anilino]-7h-purin-6-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(=C1N=CN=C1N=1)NC=1NC(C=C1)=CC=C1CC1=CC=NC=C1 BCCAFVDIHPOCSV-LCLWPZTBSA-N 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- CSPKGUCKMUMGIG-UHFFFAOYSA-N 6-phenylthieno[3,2-d]pyrimidine-2,4-diamine Chemical compound C=1C2=NC(N)=NC(N)=C2SC=1C1=CC=CC=C1 CSPKGUCKMUMGIG-UHFFFAOYSA-N 0.000 claims 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 1
- TZGDXHITFVTUJO-UHFFFAOYSA-N CC(C=C(C=C1)C2=C3C(N)=NC(N)=NC3=CC=C2)=C1OCCN1CCCC1 Chemical compound CC(C=C(C=C1)C2=C3C(N)=NC(N)=NC3=CC=C2)=C1OCCN1CCCC1 TZGDXHITFVTUJO-UHFFFAOYSA-N 0.000 claims 1
- 102000000551 Syk Kinase Human genes 0.000 claims 1
- 108010016672 Syk Kinase Proteins 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75139305P | 2005-12-15 | 2005-12-15 | |
| US60/751,393 | 2005-12-15 | ||
| PCT/US2006/062162 WO2007070872A1 (en) | 2005-12-15 | 2006-12-15 | Kinase inhibitors and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009519979A JP2009519979A (ja) | 2009-05-21 |
| JP2009519979A5 true JP2009519979A5 (enExample) | 2010-02-04 |
| JP5400388B2 JP5400388B2 (ja) | 2014-01-29 |
Family
ID=37891850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545992A Expired - Fee Related JP5400388B2 (ja) | 2005-12-15 | 2006-12-15 | キナーゼインヒビターおよびその利用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US7601713B2 (enExample) |
| EP (1) | EP1960372B1 (enExample) |
| JP (1) | JP5400388B2 (enExample) |
| CA (1) | CA2633035C (enExample) |
| ES (1) | ES2562428T3 (enExample) |
| WO (1) | WO2007070872A1 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006119504A2 (en) * | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
| JP5400388B2 (ja) * | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターおよびその利用 |
| TW200808360A (en) * | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
| WO2008045978A1 (en) * | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
| BRPI0722383A2 (pt) | 2006-12-08 | 2012-06-05 | Irm Llc | compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos |
| CA2673965A1 (en) | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | Pyrazolopyrimidine compound |
| WO2009005813A1 (en) * | 2007-07-02 | 2009-01-08 | Wyeth | Modulators of axl for use in treating bone disorders |
| RU2472797C2 (ru) * | 2007-08-08 | 2013-01-20 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА |
| WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| US20090088371A1 (en) * | 2007-08-28 | 2009-04-02 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
| EP2217716A4 (en) | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS |
| AU2008323628B2 (en) * | 2007-11-15 | 2013-10-17 | Ym Biosciences Australia Pty Ltd | N-containing heterocyclic compounds |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| MX2010011463A (es) | 2008-04-16 | 2011-06-03 | Portola Pharm Inc | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| JP2011518219A (ja) * | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| KR20110033223A (ko) * | 2008-06-20 | 2011-03-30 | 제넨테크, 인크. | 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법 |
| US20100035875A1 (en) * | 2008-06-20 | 2010-02-11 | Bing-Yan Zhu | Triazolopyridine jak inhibitor compounds and methods |
| RU2555326C2 (ru) | 2009-01-16 | 2015-07-10 | Риджел Фармасьютикалз, Инк. | ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА |
| JP2012517426A (ja) * | 2009-02-09 | 2012-08-02 | アステックス ファーマシューティカルズ インコーポレイテッド | ピロロピリミジニルａｘｌキナーゼ阻害剤 |
| WO2010114894A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted heterocyclic compounds |
| CN105037364B (zh) * | 2009-04-03 | 2018-04-27 | 维拉斯通股份有限公司 | 作为激酶抑制剂的嘧啶取代的嘌呤化合物 |
| CN102428085B (zh) * | 2009-04-03 | 2015-07-15 | 维拉斯通股份有限公司 | 作为激酶抑制剂的嘧啶取代的嘌呤化合物 |
| EP2459558A2 (en) | 2009-07-30 | 2012-06-06 | Irm Llc | Compounds and compositions as syk kinase inhibitors |
| TW201105669A (en) * | 2009-07-30 | 2011-02-16 | Irm Llc | Compounds and compositions as Syk kinase inhibitors |
| BR112012002336A2 (pt) * | 2009-08-07 | 2016-05-31 | Merck Patent Gmbh | compostos aza-heterocíclicos |
| KR101094446B1 (ko) | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| DK2516434T3 (en) * | 2009-12-23 | 2015-08-31 | Takeda Pharmaceutical | FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS |
| EP2441755A1 (en) * | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| FR2967854A1 (fr) * | 2010-11-19 | 2012-05-25 | France Telecom | Procede de communication dans un reseau cooperatif |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| HRP20181286T1 (hr) | 2011-03-10 | 2018-10-05 | Rigel Pharmaceuticals, Inc. | 2,4 supstituirani pirimidindiamini za uporabu kod diskoidnog lupusa |
| AU2012253885A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Aminopyrimidines as Syk inhibitors |
| CA2834062A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| US9145391B2 (en) | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
| WO2012177714A1 (en) * | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| WO2013052393A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2763974B1 (en) | 2011-10-05 | 2016-09-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| SG11201402570QA (en) | 2011-11-23 | 2014-06-27 | Portola Pharm Inc | Pyrazine kinase inhibitors |
| MY165215A (en) | 2012-01-31 | 2018-03-09 | Daiichi Sankyo Co Ltd | Pyridone derivatives |
| WO2013162061A1 (ja) * | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
| WO2013192128A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| EP2863914B1 (en) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| EP2863916B1 (en) | 2012-06-22 | 2018-07-18 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (syk) inhibitors |
| US9416111B2 (en) | 2012-06-22 | 2016-08-16 | Merck Sharp & Dohme Corp. | Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| WO2014018535A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| US9353066B2 (en) | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
| JP2015528501A (ja) | 2012-09-12 | 2015-09-28 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 白斑の治療法 |
| US9586931B2 (en) | 2012-09-28 | 2017-03-07 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as Syk inhibitors |
| US9624210B2 (en) | 2012-12-12 | 2017-04-18 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors |
| US9598405B2 (en) | 2012-12-21 | 2017-03-21 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| WO2014176210A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| EP2988749B1 (en) | 2013-04-26 | 2019-08-14 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| EP3083560B1 (en) | 2013-12-20 | 2021-10-27 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| US9783531B2 (en) | 2013-12-20 | 2017-10-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| TWI690525B (zh) | 2014-07-07 | 2020-04-11 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| US10611765B2 (en) | 2014-11-06 | 2020-04-07 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors |
| ES2788454T3 (es) * | 2014-12-18 | 2020-10-21 | Takeda Pharmaceuticals Co | Formas en estado sólido de pirrolidinonas heteroaromáticas condensadas |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| ES2896079T3 (es) | 2016-02-26 | 2022-02-23 | Ono Pharmaceutical Co | Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario |
| CN114456176B (zh) | 2016-03-28 | 2024-08-30 | 因赛特公司 | 作为tam抑制剂的吡咯并三嗪化合物 |
| CN107698603B (zh) * | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| EP3673907A4 (en) | 2017-08-23 | 2020-08-19 | ONO Pharmaceutical Co., Ltd. | CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT |
| KR102739325B1 (ko) | 2017-09-27 | 2024-12-09 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
| US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
| US12012408B2 (en) | 2018-06-22 | 2024-06-18 | The Royal Institution For The Advancement Of Learning/Mcgill University | Purine compounds and method for the treatment of cancer |
| US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
| US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| PH12022552347A1 (en) | 2020-03-06 | 2024-01-29 | Incyte Corp | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| EP4526469A1 (en) | 2022-05-16 | 2025-03-26 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
| WO2024054793A1 (en) | 2022-09-09 | 2024-03-14 | University Of Rochester | Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength |
| WO2026093435A1 (en) | 2024-10-31 | 2026-05-07 | Institut National de la Santé et de la Recherche Médicale | Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT874846E (pt) * | 1995-11-01 | 2003-08-29 | Novartis Ag | Derivados de purina e processos para a sua preparacao |
| WO1997020821A1 (en) * | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
| AU7692896A (en) * | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
| GB9903762D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9918035D0 (en) | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| AU1071301A (en) | 1999-11-01 | 2001-05-14 | Eli Lilly And Company | Pharmaceutical compounds |
| FR2818642B1 (fr) * | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| AU2002334992B2 (en) * | 2001-10-12 | 2009-07-02 | Irm Llc | Methods for the synthesis of substituted purines |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US6897307B2 (en) * | 2002-03-28 | 2005-05-24 | Novartis Ag | Process for preparing 2,6-diaminopurine derivatives |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| WO2004043367A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
| EP1643936B1 (en) | 2003-07-14 | 2010-08-11 | University of Limerick | A vascular graft |
| MXPA06001758A (es) * | 2003-08-15 | 2006-08-11 | Irm Llc | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. |
| US7592177B2 (en) * | 2003-11-10 | 2009-09-22 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| GEP20094720B (en) * | 2003-12-16 | 2009-06-25 | Pfizer Prod Inc | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| GB0407723D0 (en) * | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
| US7754714B2 (en) * | 2004-05-18 | 2010-07-13 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| CN101031551A (zh) * | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂 |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| ATE421996T1 (de) | 2004-11-15 | 2009-02-15 | Rigel Pharmaceuticals Inc | Verfahren zur herstellung optisch aktiver n- carbamat-geschützter beta-lactame durch optische auflösung unter verwendung einer candida antarctica lipase |
| WO2006105056A2 (en) * | 2005-03-28 | 2006-10-05 | Fmc Corporation | Insecticidal 2,4-diaminoquinazolines and related derivatives |
| CN100526315C (zh) * | 2005-06-16 | 2009-08-12 | 浙江医药股份有限公司新昌制药厂 | N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途 |
| US20080004295A1 (en) * | 2005-10-13 | 2008-01-03 | Gore Paul M | Novel compounds |
| JP5400388B2 (ja) * | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターおよびその利用 |
-
2006
- 2006-12-15 JP JP2008545992A patent/JP5400388B2/ja not_active Expired - Fee Related
- 2006-12-15 EP EP06840283.3A patent/EP1960372B1/en not_active Not-in-force
- 2006-12-15 ES ES06840283.3T patent/ES2562428T3/es active Active
- 2006-12-15 WO PCT/US2006/062162 patent/WO2007070872A1/en not_active Ceased
- 2006-12-15 US US11/611,568 patent/US7601713B2/en active Active
- 2006-12-15 CA CA2633035A patent/CA2633035C/en active Active
-
2009
- 2009-09-01 US US12/552,125 patent/US8053434B2/en active Active
-
2011
- 2011-09-23 US US13/242,994 patent/US9096542B2/en active Active
-
2015
- 2015-06-30 US US14/754,989 patent/US9834568B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6754864B2 (ja) | Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| CN103748096B (zh) | 作为蛋白激酶抑制剂的吡咯并嘧啶化合物 | |
| KR101917972B1 (ko) | ERK 억제제로서 티에노[2,3-c]피롤-4-온 유도체 | |
| AU2013300344B2 (en) | N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer | |
| Wu et al. | Design and synthesis of tetrahydropyridothieno [2, 3-d] pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency | |
| AU2010286569B2 (en) | Compounds and compositions as protein kinase inhibitors | |
| US20170224689A1 (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| Dehnhardt et al. | Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402 | |
| JP2022542396A5 (enExample) | ||
| EA034558B1 (ru) | 4-ИМИДАЗО[1,5-a]ПИРИДАЗИН-1-ИЛ-БЕНЗАМИДЫ В КАЧЕСТВЕ Btk-ИНГИБИТОРОВ | |
| NZ627709A (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
| AU2008260772A1 (en) | Novel amide derivative for inhibiting the growth of cancer cells | |
| AU2010267815B2 (en) | Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | |
| JP2016528298A5 (enExample) | ||
| WO2015192658A1 (zh) | 一种新型布鲁顿酪氨酸激酶抑制剂 | |
| US20210261554A1 (en) | Ripk2 inhibitors and method of treating cancer with same | |
| ES2627428T3 (es) | Nuevos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona, su preparación y su utilización farmacéutica | |
| EP3298015A1 (en) | Compounds | |
| AU2015274285C1 (en) | Pyrimidine compounds and methods using the same | |
| RU2838180C1 (ru) | Соединения и композиции для модуляции киназной активности мутантов egfr | |
| JP2025536982A (ja) | 改良されたＮＦ－κＢ誘導キナーゼ（ＮＩＫ）阻害剤 | |
| Hamed | Design and synthesis of novel quinazoline-based EGFR kinase inhibitors and dual EGFR/NF-kappa B inhibitors as potential anti-cancer drugs with enhanced efficacy | |
| HK1191936B (en) | Compounds and compositions as protein kinase inhibitors |